Payment overview · 2025
General Payments
$666.49
34 reported records · 16 companies
Healthcare provider profile · identity verified
Stanley W Koch, MD
Allopathic & Osteopathic Physicians|Family Medicine · MORTON, IL · NPI 1467436436
Verified facts
What the public records show
CMS Open Payments records show Stanley W Koch, MD received $666.49 in general payments during 2025 across 34 reported records.
PFIZER INC. accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $111.11 | 16.7% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $73.18 | 11.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $67.40 | 10.1% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.78 | 10.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.54 | 7.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.92 | 7.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.38 | 6.1% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $33.81 | 5.1% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $32.89 | 4.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.69 | 3.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.24 | 3.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.06 | 3.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.66 | 3.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.37 | 2.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.59 | 2.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.87 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $666.49 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $111.11 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $111.11 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $67.40 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $66.78 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $47.92 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $39.68 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $33.81 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.50 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.50 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $32.89 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.69 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $25.06 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
86 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 567 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 460 | 84 |
| Omeprazole | Omeprazole | 366 | 66 |
| Lisinopril | Lisinopril | 362 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 343 | 73 |
| Metformin Hcl | Metformin Hcl | 251 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 251 | 74 |
| Losartan Potassium | Losartan Potassium | 240 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 29 |
| Gabapentin | Gabapentin | 164 | 42 |
| Simvastatin | Simvastatin | 155 | 34 |
| Baclofen | Baclofen | 145 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 28 |
| Warfarin Sodium | Warfarin Sodium | 128 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 27 |
| Montelukast Sodium | Montelukast Sodium | 108 | 16 |
| Allopurinol | Allopurinol | 107 | 20 |
| Furosemide | Furosemide | 104 | 24 |
| Famotidine | Famotidine | 90 | 11 |
| Potassium Chloride | Potassium Chloride | 89 | 14 |
| Eliquis | Apixaban | 86 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 17 |
| Glimepiride | Glimepiride | 81 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 78 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 16 |
| Donepezil Hcl | Donepezil Hcl | 75 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 74 | 11 |
| Diazepam | Diazepam | 71 | 13 |
| Sertraline Hcl | Sertraline Hcl | 68 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 19 |
| Atenolol | Atenolol | 63 | 11 |
| Buspirone Hcl | Buspirone Hcl | 62 | suppressed |
| Ramipril | Ramipril | 61 | suppressed |
| Xarelto | Rivaroxaban | 61 | suppressed |
| Jardiance | Empagliflozin | 59 | 14 |
| Tramadol Hcl | Tramadol Hcl | 59 | 18 |
| Lorazepam | Lorazepam | 56 | 15 |
| Memantine Hcl | Memantine Hcl | 55 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 11 |
| Finasteride | Finasteride | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 51 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 49 | suppressed |
| Alprazolam | Alprazolam | 46 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 37 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 23 |
| Spironolactone | Spironolactone | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 12 |
| Latanoprost | Latanoprost | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 26 |
| Azithromycin | Azithromycin | 32 | 27 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 17 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | 11 |
| Carvedilol | Carvedilol | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 18 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Zypitamag | Pitavastatin Magnesium | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Travoprost | Travoprost | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Aviane | Levonorgestrel/Ethin.Estradiol | 11 | suppressed |
| Terbutaline Sulfate | Terbutaline Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $666.49 · 34 records | PFIZER INC. | EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, REXULTI, Tymlos, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error